<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04145232</url>
  </required_header>
  <id_info>
    <org_study_id>A.I.mmune</org_study_id>
    <secondary_id>RPMP.01.02.01-12-0301/17</secondary_id>
    <nct_id>NCT04145232</nct_id>
  </id_info>
  <brief_title>AImmune - Artificial Intelligence Algorithm for Identification of Immunogenic Neoepitopes of Cancer to Predict and Boost Patient's Response to Immunotherapies.</brief_title>
  <official_title>Development of AImmune Technology as a Bioinformatic Component of Diagnostic Tests Used in Cancer Immunotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ardigen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Małopolskie Centre of Entrepreneurship</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ardigen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the project is to develop and validate A.I.mmune technology. It performs complex
      analyses of patients' tumor and immune system state using data derived from next-generation
      sequencing of tumor and healthy tissue to identify cancer neoantigens, which are likely to
      elicit an immune response.

      A key challenge to be solved using the technology is to predict for each patient which
      neoepitopes are not only likely to bind to HLA or be presented on the tumor cell surface, but
      also will be recognized by the T-cell receptor and create the immunogenic response. The
      presence of such epitopes is required for immunotherapy by immune checkpoint inhibition to
      have an effect on the disease. Knowledge of those epitopes enables therapeutic strategies to
      boost the immune response by designing personalized cancer vaccines and adoptive cell
      therapies.

      The samples and data collected in this clinical study will be used for clinical validation of
      A.I.mmune technology. For all patients treated with immunotherapy (using anti-PD1 / anti-PDL1
      and / or anti-CTLA-4 antibodies) peripheral blood samples (PBMC) and biopsy (FFPE) collection
      will be performed before treatment. Samples will be sequenced by next-generation sequencing
      platform. In parallel, the investigators will also collect samples of stool (one sample
      before the start of immunotherapy) and follow-up information of responses to treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 13, 2019</start_date>
  <completion_date type="Anticipated">November 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Responders and Non-responders on immunotherapy (evaluated using RECIST 1.1 criteria)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Standard follow-up care after cancer treatment.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>Neoepitopes</condition>
  <condition>Neoantigens</condition>
  <condition>Immunotherapy</condition>
  <condition>Next Generation Sequencing (NGS)</condition>
  <condition>Personalized Neoantigen Cancer Vaccine</condition>
  <arm_group>
    <arm_group_label>NSCLC</arm_group_label>
    <description>This cohort will consist of 30 patients with non-small cell lung cancer (NSCLC).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Collection of biopsy (FFPE), blood (PBMC) and stool</intervention_name>
    <description>Patients receiving routine treatment (immunotherapy using anti-PD1 / anti-PDL1 and / or anti CTLA4 antibodies), financed by the Polish National Health Fund (NFZ).</description>
    <arm_group_label>NSCLC</arm_group_label>
    <other_name>Nivolumab</other_name>
    <other_name>Ipilimumab</other_name>
    <other_name>Atezolizumab</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      biopsy (FFPE), peripheral blood samples (PBMC) and stool
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients receiving routine treatment.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women ≥18 years of age.

          -  Patients with non-small cell lung cancer.

          -  Patients with informed consent to participate in the study.

          -  Patients receiving routine treatment (immunotherapy using anti-PD1 / anti-PDL1 and /
             or anti CTLA4 antibodies), financed by the Polish National Health Fund (NFZ).

          -  The applied immunotherapy should be the first or second line of treatment.

        Exclusion Criteria:

          -  Patients who are unable to understand, read and / or sign informed consent.

          -  Patients who can not collect stools.

          -  Patients with fecal transplant.

          -  The applied immunotherapy is not the first or second line of treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Piotr Stepniak</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ardigen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emilia Strycharz-Angrecka</last_name>
    <phone>+48 12 340 94 94</phone>
    <email>emilia.strycharz-angrecka@ardigen.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bozena Augustyn</last_name>
    <phone>+48 12 340 94 94</phone>
    <email>bozena.augustyn@ardigen.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Clinical Centre in Gdansk</name>
      <address>
        <city>Gdańsk</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 29, 2019</study_first_submitted>
  <study_first_submitted_qc>October 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2019</study_first_posted>
  <last_update_submitted>October 29, 2019</last_update_submitted>
  <last_update_submitted_qc>October 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>Non Small Cell Lung Cancer</keyword>
  <keyword>Neoepitopes</keyword>
  <keyword>Neoantigens</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Nivolumab</keyword>
  <keyword>Ipilimumab</keyword>
  <keyword>Atezolizumab</keyword>
  <keyword>Neoantigen cancer vaccine</keyword>
  <keyword>Personalized neoantigen cancer vaccine</keyword>
  <keyword>FFPE</keyword>
  <keyword>PBMC</keyword>
  <keyword>Stool</keyword>
  <keyword>Immuno-Oncology</keyword>
  <keyword>Next generation sequencing (NGS)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

